LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2012. The Company reported a net loss applicable to common stock of $25.9 million, or $1.29 per share, for the quarter ended September 30, 2012. Net loss applicable to common stock for the nine months ended September 30, 2012, was $52.4 million, or $2.62 per share. Net cash used in operating activities for the quarter ended September 30, 2012, was $7.6 million. Net cash used in operating activities for the nine months ended September 30, 2012, was $19.2 million.
